Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881113 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
A Phase 3 study of Allergic Conjunctivitis, sponsored by Aciex Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT01881113 is a Phase 3 study of Allergic Conjunctivitis that has completed, run by Aciex Therapeutics. The registered enrollment target is 101 participants, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01881113, a Phase 3 study of Allergic Conjunctivitis, has completed, sponsored by Aciex Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
Conditions Studied
Interventions
- DRUG AC-170 0.24%
- DRUG AC-170 0%
Study Locations (1)
Massachusetts
- Ora, Inc. - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01881113
The ClinicalTrials.gov registry entry for NCT01881113 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% lower). The listed sponsor is Aciex Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which AC-170 0.24% is the first listed.
NCT01881113 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01881113 about?
NCT01881113 is a clinical study titled "A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle". The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
What is the current status of trial NCT01881113?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2013-06. Estimated completion is 2013-10.
What conditions does trial NCT01881113 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01881113?
The interventions under investigation include: AC-170 0.24% (DRUG), AC-170 0% (DRUG).
Who is sponsoring clinical trial NCT01881113?
This trial is sponsored by Aciex Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01881113 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
COMPLETED · Phase 3
-
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
COMPLETED · Phase 3
-
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
COMPLETED · Phase 3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.